Skip to content

Catheterisation for chronic subdural hematoma

Neuroendovascular treatment for chronic subdural hematoma trial - CSHNET

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000057789
Enrollment
200
Registered
2025-07-01
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic subdural hematoma

Interventions

neuroendovascular therapy conventional therapy

Sponsors

South Miyagi Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients must be at least 20 years old with a diagnosis of chronic subdural haematoma on CT. Medical treatment or follow-up is the treatment of choice if symptoms (neurological local symptoms such as gait disturbance, cognitive impairment, impaired consciousness, paralysis and headache) are minor, while surgical treatment is the treatment of choice for all but the most minimally symptomatic cases

Exclusion criteria

Exclusion criteria: Persons who have undergone craniotomy within 6 months. Persons with a history of shunt surgery. Persons suspected of having low medullary pressure syndrome. Other persons deemed unsuitable by the researcher.

Design outcomes

Primary

MeasureTime frame
Recurrence rate (patients with a relapse within one month are defined to have relapsed); mesure mRS at three months and one year.

Countries

Japan

Contacts

Public ContactTakashi Inoue

South Miyagi Medical Center Department of Neurosurgery

t.inoue@southmiyagi-mc.jp0224-51-5500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026